Search results
Apr 18, 2022 · Our combination of focused innovation and commercial scale brings differentiated products to market that benefit patients, customers and health care providers. AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives.
Nov 30, 2023 · NORTH CHICAGO, Ill., and WALTHAM, Mass., Nov. 30, 2023 / PRNewswire / -- AbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE ® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC ...
Mar 25, 2024 · NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 / PRNewswire / -- AbbVie Inc. (NYSE: ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients ...
May 7, 2024 · 200,000+. patients and healthcare providers reached through our independent healthcare grants in 2022. From drug discovery and development to ensuring our medicines are accessible and affordable, patient needs are what guide our work.
Oct 11, 2023 · NORTH CHICAGO, Ill., Oct. 11, 2023 / PRNewswire / -- AbbVie (NYSE: ABBV) today announced that its Phase 2b study evaluating upadacitinib (RINVOQ ®) in adults with non-segmental vitiligo (NSV) met the primary endpoint of percent change from baseline in the Facial Vitiligo Area Scoring Index (F-VASI) at week 24 with the 11 mg and 22 mg doses ...
Feb 12, 2024 · AbbVie expects its acquisition of ImmunoGen to be accretive to AbbVie's diluted EPS beginning in 2027 and significantly accretive over the long-term. Full-Year 2024 Outlook. AbbVie is reaffirming its previously issued 2024 full-year adjusted diluted EPS guidance range of $11.05 - $11.25.
Our online application is for use by people over the age of eighteen and seeking assistance (the patient) for either HUMIRA ® (adalimumab), SKYRIZI ® (risankizumab-rzaa) RINVOQ ® (upadacitinib) or MAVYRET ® (glecaprevir/pibrentasvir). We will ask you to register and complete an application.
